secwatch.observer — SEC 8-K summary
======================================

Issuer:     Tonix Pharmaceuticals Holding Corp. (TNXP)
CIK:        0001430306
Form:       8-K
Filed at:   2025-07-09T23:59:59+00:00
Accession:  0001999371-25-008877
Event type: regulatory
Sentiment:  positive
Materiality: 0.90
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud

Tonix Pharmaceuticals Announces Publication of Phase 3 RESILIENT Trial Data for TNX-102 SL
--------------------------------------------------------------------------------

- Full results from confirmatory Phase 3 RESILIENT trial of TNX-102 SL published online in Pain Medicine on July 9, 2025.
- TNX-102 SL achieved statistically significant improvement in primary endpoint of reducing fibromyalgia pain vs placebo (LS mean reduction 1.8 vs 1.2 points).
- Statistically significant improvements observed across all six prespecified key secondary endpoints.
- FDA PDUFA target date for TNX-102 SL is August 15, 2025; if approved, would be first new fibromyalgia drug in over 15 years.
- TNX-102 SL was generally well tolerated; most common AEs were mild oral tingling/numbness and aftertaste, no drug-related serious AEs.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1430306/000199937125008877/0001999371-25-008877-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1430306/000199937125008877/tnxp-8k_070925.htm
  HTML page:      https://secwatch.observer/filing/0001999371-25-008877

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer